Agendia Demonstrates MammaPrint Utility in Predicting Chemotherapy Benefit Over 5 Years in Patients with HR+HER2- Early Breast Cancer at SABCS 2024
New data reinforces findings from MINDACT supporting MammaPrintยฎ in Read More
New data reinforces findings from MINDACT supporting MammaPrintยฎ in Read More
A secondary analysis of the randomized controlled trial, IDEAL, Read More
New data reinforces MammaPrintยฎ and BluePrintยฎ testsโ expanding clinical Read More
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS, November 14, 2024 Read More
This achievement highlights the remarkable seven-year progression of FLEX Read More
Agendia Achieves CE-IVDR Certification for its MammaPrint and BluePrint Breast Cancer Assays
Read MoreMammaPrint 70-gene Assay Evaluated in the NRG Oncology/NSABP B-42 Trial
Read MoreElucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer
Read MoreAssociation of MammaPrint index and 3-year outcome of patients in the FLEX Registry trial with HR+HER2- early-stage breast cancer treated with chemotherapy with or without anthracycline
Read MoreAgendia to Unveil Robust Suite of Data at 2024 ASCO to Further Advance Breast Cancer Care
Read More